The experimental substantiation of advisability of introducing an adjuvant to the composition of the immunobiological solution “Candidocyde”
DOI:
https://doi.org/10.24959/cphj.14.1325Keywords:
candidiasis, antigen, vaccine, immunity, adjuvantAbstract
Candidal disease is growing around the world, and it is associated with a wide administration of antimicrobial, hormonal medicines and cytostatic drugs. To fight candidal infections the studies in developing vaccines against candidiasis are carried out actively in recent years in the world. At the premises of the National University of Pharmacy at the Biotechnology Department and the Department of Microbiology, Virology and Immunology the authors have developed a potential vaccine – the immunobiological solution “Candidocyde” based on the associated antigens of C. albicans and C. tropicalis fungi obtained by using ultrasound. For the purpose of the experimental substantiation of advisability of introducing an adjuvant to the composition of the immunobiological solution “Candidocyde” developed for preventing and treating candidal infections and based on the antigens of C. albicans and C. tropicalis fungi with the protein concentration of 3 mg/ml the samples of the solution “Candidocyde” separately with aluminium hydroxide and aluminium phosphate as adjuvants have been prepared and studied. The studies were performed in white mice with six animals in the group. The experimental samples in the volume of 0.2 ml were injected intramuscularly twice with the interval of 14 days. According to the results of the research conducted it has been found that the immunobiological solution “Candidocyde” based on the antigens of C. albicans and C. tropicalis fungi with the protein concentration of 3 mg/ml and the adjuvant under study with two intramuscular injections in the volume of 0.2 ml does not provide efficiency increase when preventing and treating candidal infections. Therefore, the adjuvant introduction into the composition of the immunobiological solution “Candidocyde” is impractical.
References
Атауллаханов Р.И., Хаитов Р.М. // Иммунол. – 2011. – Т. 32, №1. – С. 37-45.
Голубка О.В. // Annals of Mechnikov Institute. – 2011. – №2. – С. 51-59.
Жукова Н.В., Кривошеева И.М. // Кримський терапевт. журн. – 2013. – №2. – С. 99-104.
Краснопольский Ю.М., Борщевская М.И. Фармацевтическая биотехнология. Технология производства иммунобиологических препаратов. – Х.: НТУ «ХПИ», 2009. – 352 c.
Перцев І.М., Дмитрієвський Д.І., Рибачук В.Д. та ін. Допоміжні речовини в технології ліків: вплив на технологічні, споживчі, економічні характеристики і терапевтичну ефективність: Навч. посіб. / За ред. І.М.Перцева. – Х.: Золоті сторінки, 2010. – 598 с.
Петров Р.В., Хаитов Р.М. Иммуногены и вакцины нового поколения. – М.: ГЭОСТАР-Медицина, 2011. – 608 с.
Чуєшов В.І., Гладух Є.В., Сайко І.В. та ін. Технологія ліків промислового виробництва: Підруч. для студ. вищ. навч. закл.: у 2-х ч. – 2-е вид., перероб. і доп. – Х.: НФаУ; Оригінал, 2012. – Ч. 1. – 694 с.
Cassone A. // Nature Rev. Microbiol. – 2013. – Vol. 11. – P. 884-891.
Exley C., Siesjo P., Eriksson H. // Trends Immunol. – 2010. – Vol. 4, №23. – P. 103-109.
Grover A., Bhandari B.S., Rai N., Lakhera P.C. // Biotechnol. Intern. – 2010. – Vol. 3, №1. – P. 4-17.
Shaw C.A., Petrik M.S. // J. Inorg. Biochem. – 2009. – Vol. 11, №103. – P. 1555-1562.
Shoenfeld Y., Agmon-Levin N. // J. Autoimmunol. – 2011. – Vol. 1, №36. – P. 4-8.
Tomljenovic L. // J. Alzheimers. Dis. – 2011. – Vol. 4, №23. – P. 567-598.
Tomljenovic L., Shaw C.A. // Current Med. Chemistry. – 2011. – №18. – P. 2630-2637.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
